STAAR Surgical Appoints Scott Barnes, MD, as New CMO

October 6, 2017: By Jon Swedien

STAAR Surgical logoSTAAR Surgical has appointed Scott D. Barnes, MD, to be its chief medical officer, a newly created position, the Monrovia, California, company announced Oct. 2.

Barnes will report to Caren Mason, STAAR’s president and CEO.

He will also serve on the executive management team and provide strategic guidance for STAAR’s medical affairs, professional affairs, and product development pathways. As well, Barnes will lead the company’s surgeon training, certification programs, and surgeon working groups, STAAR said.

Since 2012, Barnes has served as chief of ophthalmology services at Womack Army Medical Center in Fort Bragg, North Carolina.

Barnes has personally implanted more than 3,000 implantantable contact lenses in the eyes of soldiers, STAAR said.

He joined Womack in 2004 as chief of ophthalmology and refractive surgery and served as a theater ophthalmology consultant in Iraq and Afghanistan during 2005. In 2006, he returned to Womack as chief of refractive surgery, and, in 2008, he was designated Army Surgeon General A, which is similar to the professor level in a civilian institution.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023